跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ POMALIDOMIDE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ POMALIDOMIDE
Authorized
STANDARD
SANDOZ POMALIDOMIDE
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
67954a861ae1aa32
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
67954a861ae1aa32
Drug Approval Canada Name
SANDOZ POMALIDOMIDE
Product Name
SANDOZ POMALIDOMIDE
Status
Marketed
Status Date
2023-02-28
Original Market Date
2023-02-28
Din
02524007
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L04AX06 POMALIDOMIDE
Atc Name
l 04 ax 06
Aig Number
0155290003
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
POMALIDOMIDE
3 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
67954a861ae1aa32
Type
Standard
Back to Health Canada Approvals